|Bid||157.94 x 100|
|Ask||158.06 x 200|
|Day's Range||157.46 - 163.32|
|52 Week Range||71.46 - 167.86|
|PE Ratio (TTM)||219.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Zacks.com featured highlights: Farmers & Merchants Bancorp, Advanced Energy Industries, NVR, Vertex Pharmaceuticals and Sanderson Farms
Vertex Pharmaceuticals Incorporated's (VRTX) Q2 results were encouraging, as it topped earnings and revenues expectations backed by higher sales of both its CF drugs.
J.P. Morgan analyst Cory Kasimov is getting more upbeat on two biotech players on the heels of aces from both handed over with second quarterly results yesterday. Between Gilead Sciences, Inc. (NASDAQ:GILD) showing it remains a force to be reckoned with in the HIV sphere even in face of a derailing HCV segment and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) exciting cystic fibrosis prospects, the analyst has every confidence these two stocks are one to watch in the biotech-verse. Gilead delivered a reassuring second-quarter print yesterday that has Kasimov highlighting promise for this biotech giant- even with its HCV weakness.